Read Books Online and Download eBooks, EPub, PDF, Mobi, Kindle, Text Full Free.
Drug Targets In Cellular Processes Of Cancer From Nonclinical To Preclinical Models
Download Drug Targets In Cellular Processes Of Cancer From Nonclinical To Preclinical Models full books in PDF, epub, and Kindle. Read online Drug Targets In Cellular Processes Of Cancer From Nonclinical To Preclinical Models ebook anywhere anytime directly on your device. Fast Download speed and no annoying ads. We cannot guarantee that every ebooks is available!
Book Synopsis Drug Targets in Cellular Processes of Cancer: From Nonclinical to Preclinical Models by : Hardeep Singh Tuli
Download or read book Drug Targets in Cellular Processes of Cancer: From Nonclinical to Preclinical Models written by Hardeep Singh Tuli and published by Springer Nature. This book was released on 2020-09-30 with total page 228 pages. Available in PDF, EPUB and Kindle. Book excerpt: This book explores potential cellular drug targets for cancer therapy. The first couple of chapters describe conventional treatment (radiotherapy, chemotherapy, and immunotherapy) & detection (biosensors) strategies for cancer. In contrast, the subsequent chapters address the role of cyclin-dependent kinases and cell cycle regulatory proteins in the growth of cancer cells and their potential as target for cancer treatment. The book then discusses the regulation of various pro-apoptotic and anti-apoptotic proteins via chemotherapeutic drugs. In addition, it examines the molecular mechanisms that are critical for mediating autophagic cell death in cancer cells. It subsequently reviews the role of reactive oxygen (ROS) species during carcinogenesis and during chemotherapy, and the potential of anti-inflammatory routes for the development of new therapeutic modulators. Lastly, it describes therapeutic strategies that target the tumor microenvironment and various angiogenic pathways for the treatment of cancer and to develop personalized medicine. Given its scope, the book is valuable resource for oncologists, cancer researchers, clinicians, and pharmaceutical industry personnel.
Book Synopsis Anticancer Drug Development Guide by : Beverly A. Teicher
Download or read book Anticancer Drug Development Guide written by Beverly A. Teicher and published by Humana Press. This book was released on 2004-02-01 with total page 451 pages. Available in PDF, EPUB and Kindle. Book excerpt: This unique volume traces the critically important pathway by which a "molecule" becomes an "anticancer agent. " The recognition following World War I that the administration of toxic chemicals such as nitrogen mustards in a controlled manner could shrink malignant tumor masses for relatively substantial periods of time gave great impetus to the search for molecules that would be lethal to specific cancer cells. Weare still actively engaged in that search today. The question is how to discover these "anticancer" molecules. Anticancer Drug Development Guide: Preclinical Screening, Clinical Trials, and Approval, Second Edition describes the evolution to the present of preclinical screening methods. The National Cancer Institute's high-throughput, in vitro disease-specific screen with 60 or more human tumor cell lines is used to search for molecules with novel mechanisms of action or activity against specific phenotypes. The Human Tumor Colony-Forming Assay (HTCA) uses fresh tumor biopsies as sources of cells that more nearly resemble the human disease. There is no doubt that the greatest successes of traditional chemotherapy have been in the leukemias and lymphomas. Since the earliest widely used in vivo drug screening models were the murine L 1210 and P388 leukemias, the community came to assume that these murine tumor models were appropriate to the discovery of "antileukemia" agents, but that other tumor models would be needed to discover drugs active against solid tumors.
Book Synopsis Improving and Accelerating Therapeutic Development for Nervous System Disorders by : Institute of Medicine
Download or read book Improving and Accelerating Therapeutic Development for Nervous System Disorders written by Institute of Medicine and published by National Academies Press. This book was released on 2014-02-06 with total page 107 pages. Available in PDF, EPUB and Kindle. Book excerpt: Improving and Accelerating Therapeutic Development for Nervous System Disorders is the summary of a workshop convened by the IOM Forum on Neuroscience and Nervous System Disorders to examine opportunities to accelerate early phases of drug development for nervous system drug discovery. Workshop participants discussed challenges in neuroscience research for enabling faster entry of potential treatments into first-in-human trials, explored how new and emerging tools and technologies may improve the efficiency of research, and considered mechanisms to facilitate a more effective and efficient development pipeline. There are several challenges to the current drug development pipeline for nervous system disorders. The fundamental etiology and pathophysiology of many nervous system disorders are unknown and the brain is inaccessible to study, making it difficult to develop accurate models. Patient heterogeneity is high, disease pathology can occur years to decades before becoming clinically apparent, and diagnostic and treatment biomarkers are lacking. In addition, the lack of validated targets, limitations related to the predictive validity of animal models - the extent to which the model predicts clinical efficacy - and regulatory barriers can also impede translation and drug development for nervous system disorders. Improving and Accelerating Therapeutic Development for Nervous System Disorders identifies avenues for moving directly from cellular models to human trials, minimizing the need for animal models to test efficacy, and discusses the potential benefits and risks of such an approach. This report is a timely discussion of opportunities to improve early drug development with a focus toward preclinical trials.
Download or read book Tumor Organoids written by Shay Soker and published by Humana Press. This book was released on 2017-10-20 with total page 213 pages. Available in PDF, EPUB and Kindle. Book excerpt: Cancer cell biology research in general, and anti-cancer drug development specifically, still relies on standard cell culture techniques that place the cells in an unnatural environment. As a consequence, growing tumor cells in plastic dishes places a selective pressure that substantially alters their original molecular and phenotypic properties.The emerging field of regenerative medicine has developed bioengineered tissue platforms that can better mimic the structure and cellular heterogeneity of in vivo tissue, and are suitable for tumor bioengineering research. Microengineering technologies have resulted in advanced methods for creating and culturing 3-D human tissue. By encapsulating the respective cell type or combining several cell types to form tissues, these model organs can be viable for longer periods of time and are cultured to develop functional properties similar to native tissues. This approach recapitulates the dynamic role of cell–cell, cell–ECM, and mechanical interactions inside the tumor. Further incorporation of cells representative of the tumor stroma, such as endothelial cells (EC) and tumor fibroblasts, can mimic the in vivo tumor microenvironment. Collectively, bioengineered tumors create an important resource for the in vitro study of tumor growth in 3D including tumor biomechanics and the effects of anti-cancer drugs on 3D tumor tissue. These technologies have the potential to overcome current limitations to genetic and histological tumor classification and development of personalized therapies.
Book Synopsis Nanotherapeutics in Cancer by : Hardeep Singh Tuli
Download or read book Nanotherapeutics in Cancer written by Hardeep Singh Tuli and published by CRC Press. This book was released on 2022-11-24 with total page 279 pages. Available in PDF, EPUB and Kindle. Book excerpt: The applications of nanoparticulate drug delivery have gained significant attention in cancer diagnosis and treatment. Owing to their unique features and design, nanomedicines have made remarkable progress in eliminating dreadful tumors. Research in cancer nanomedicine spans multitudes of drug-delivery systems that include high tumor-targeting ability, sensitivity toward tumor microenvironments, and improved efficacy. Various nanocarriers have been developed and approved for anti-tumor drug targeting. These nanocarriers, such as liposomes, micelles, nanotubes, dendrimers, and peptides, offer several advantages including high selectivity, multifunctionality, specificity, biocompatibility, and precise control of drug release. This book provides complete information about each aspect of nanomaterials and nanotherapeutics, including synthesis, analysis, disease diagnosis, mechanistic insight, targeted drug delivery, and clinical implications in a concise and informative way. It presents simple and reader-friendly representations of the mechanisms of action of nanomaterials on cellular targets and highlights the challenges in targeted drug delivery with ongoing chemotherapeutic drugs.
Book Synopsis Antibody-Drug Conjugates by : Kenneth J. Olivier, Jr.
Download or read book Antibody-Drug Conjugates written by Kenneth J. Olivier, Jr. and published by John Wiley & Sons. This book was released on 2016-11-14 with total page 560 pages. Available in PDF, EPUB and Kindle. Book excerpt: Providing practical and proven solutions for antibody-drug conjugate (ADC) drug discovery success in oncology, this book helps readers improve the drug safety and therapeutic efficacy of ADCs to kill targeted tumor cells. • Discusses the basics, drug delivery strategies, pharmacology and toxicology, and regulatory approval strategies • Covers the conduct and design of oncology clinical trials and the use of ADCs for tumor imaging • Includes case studies of ADCs in oncology drug development • Features contributions from highly-regarded experts on the frontlines of ADC research and development
Book Synopsis Preclinical Safety Evaluation of Biopharmaceuticals by : Joy A. Cavagnaro
Download or read book Preclinical Safety Evaluation of Biopharmaceuticals written by Joy A. Cavagnaro and published by John Wiley & Sons. This book was released on 2013-03-07 with total page 1012 pages. Available in PDF, EPUB and Kindle. Book excerpt: "The goal is to provide a comprehensive reference book for the preclinicaldiscovery and development scientist whose responsibilities span target identification, lead candidate selection, pharmacokinetics, pharmacology, and toxicology, and for regulatory scientists whose responsibilities include the evaluation of novel therapies." —From the Afterword by Anthony D. Dayan Proper preclinical safety evaluation can improve the predictive value, lessen the time and cost of launching new biopharmaceuticals, and speed potentially lifesaving drugs to market. This guide covers topics ranging from lead candidate selection to establishing proof of concept and toxicity testing to the selection of the first human doses. With chapters contributed by experts in their specific areas, Preclinical Safety Evaluation of Biopharmaceuticals: A Science-Based Approach to Facilitating Clinical Trials: Includes an overview of biopharmaceuticals with information on regulation and methods of production Discusses the principles of ICH S6 and their implementation in the U.S., Europe, and Japan Covers current practices in preclinical development and includes a comparison of safety assessments for small molecules with those for biopharmaceuticals Addresses all aspects of the preclinical evaluation process, including: the selection of relevant species; safety/toxicity endpoints; specific considerations based upon class; and practical considerations in the design, implementation, and analysis of biopharmaceuticals Covers transitioning from preclinical development to clinical trials This is a hands-on, straightforward reference for professionals involved in preclinical drug development, including scientists, toxicologists, project managers, consultants, and regulatory personnel.
Book Synopsis Targeted Cancer Therapy in Biomedical Engineering by : Rishabha Malviya
Download or read book Targeted Cancer Therapy in Biomedical Engineering written by Rishabha Malviya and published by Springer Nature. This book was released on 2023-04-11 with total page 949 pages. Available in PDF, EPUB and Kindle. Book excerpt: This book highlights the role of Biomedical Engineering (BME) used in diagnosis (e.g., body scanners) and treatment (radiation therapy and minimal access surgery in order to prevent various diseases). In recent years, an important progress has been made in the expansion of biomedical microdevices which has a major role in diagnosis and therapy of cancer. When fighting cancer, efficacy and speed are of the utmost importance. A recently developed microfluidic chip has enabled a breakthrough in testing the efficacy of specialized cancer drugs. Effective cancer-targeting therapies will require both passive and active targeting strategies and a thorough understanding of physiologic barriers to targeted drug delivery. Targeted cancer treatments in development and the new combinatorial approaches show promise for improving targeted anticancer drug delivery and improving treatment outcomes. This book discusses the advancements and innovations in the field of BME that improve the diagnosis and treatment of cancer. This book is focused on bioengineering approaches to improve targeted delivery for cancer therapeutics, which include particles, targeting moieties, and stimuli-responsive drug release mechanisms. This book is a useful resource for students, researchers, and professionals in BME and medicine.
Author :National Academies of Sciences, Engineering, and Medicine Publisher :National Academies Press ISBN 13 :030944232X Total Pages :135 pages Book Rating :4.3/5 (94 download)
Book Synopsis Policy Issues in the Clinical Development and Use of Immunotherapy for Cancer Treatment by : National Academies of Sciences, Engineering, and Medicine
Download or read book Policy Issues in the Clinical Development and Use of Immunotherapy for Cancer Treatment written by National Academies of Sciences, Engineering, and Medicine and published by National Academies Press. This book was released on 2016-12-10 with total page 135 pages. Available in PDF, EPUB and Kindle. Book excerpt: Immunotherapy is a form of cancer therapy that harnesses the body's immune system to destroy cancer cells. In recent years, immunotherapies have been developed for several cancers, including advanced melanoma, lung cancer, and kidney cancer. In some patients with metastatic cancers who have not responded well to other treatments, immunotherapy treatment has resulted in complete and durable responses. Given these promising findings, it is hoped that continued immunotherapy research and development will produce better cancer treatments that improve patient outcomes. With this promise, however, there is also recognition that the clinical and biological landscape for immunotherapies is novel and not yet well understood. For example, adverse events with immunotherapy treatment are quite different from those experienced with other types of cancer therapy. Similarly, immunotherapy dosing, therapeutic responses, and response time lines are also markedly different from other cancer therapies. To examine these challenges and explore strategies to overcome them, the National Academies of Sciences, Engineering, and Medicine held a workshop in February and March of 2016. This report summarizes the presentations and discussions from the workshop.
Author :National Academies of Sciences, Engineering, and Medicine Publisher :National Academies Press ISBN 13 :0309457971 Total Pages :145 pages Book Rating :4.3/5 (94 download)
Book Synopsis The Drug Development Paradigm in Oncology by : National Academies of Sciences, Engineering, and Medicine
Download or read book The Drug Development Paradigm in Oncology written by National Academies of Sciences, Engineering, and Medicine and published by National Academies Press. This book was released on 2018-02-12 with total page 145 pages. Available in PDF, EPUB and Kindle. Book excerpt: Advances in cancer research have led to an improved understanding of the molecular mechanisms underpinning the development of cancer and how the immune system responds to cancer. This influx of research has led to an increasing number and variety of therapies in the drug development pipeline, including targeted therapies and associated biomarker tests that can select which patients are most likely to respond, and immunotherapies that harness the body's immune system to destroy cancer cells. Compared with standard chemotherapies, these new cancer therapies may demonstrate evidence of benefit and clearer distinctions between efficacy and toxicity at an earlier stage of development. However, there is a concern that the traditional processes for cancer drug development, evaluation, and regulatory approval could impede or delay the use of these promising cancer treatments in clinical practice. This has led to a number of effortsâ€"by patient advocates, the pharmaceutical industry, and the Food and Drug Administration (FDA)â€"to accelerate the review of promising new cancer therapies, especially for cancers that currently lack effective treatments. However, generating the necessary data to confirm safety and efficacy during expedited drug development programs can present a unique set of challenges and opportunities. To explore this new landscape in cancer drug development, the National Academies of Sciences, Engineering, and Medicine developed a workshop held in December 2016. This workshop convened cancer researchers, patient advocates, and representatives from industry, academia, and government to discuss challenges with traditional approaches to drug development, opportunities to improve the efficiency of drug development, and strategies to enhance the information available about a cancer therapy throughout its life cycle in order to improve its use in clinical practice. This publication summarizes the presentations and discussions from the workshop.
Book Synopsis Recent Advances in Cancer Diagnostics and Therapy by : Anjana Pandey
Download or read book Recent Advances in Cancer Diagnostics and Therapy written by Anjana Pandey and published by CRC Press. This book was released on 2022-01-18 with total page 233 pages. Available in PDF, EPUB and Kindle. Book excerpt: This book provides information about different types and stages of cancer and their subtypes with their respective molecular mechanisms, etiology, histopathology, and cellular origins. This book also provides detailed information about cancer incidence, mortality, and different types of technologies both bio and nano employed in cancer diagnosis and screening, and their applications in cancer therapies. This book informs readers about molecular mechanisms of cancer, diagnosis, and therapies along with different computational techniques used on a single platform. The chapters include a broad and integrated perspective on cancer-related topics. This book covers both conventional and emerging techniques employed in cancer screening and diagnosis, including imaging, biomarker, and electrochemical nanosensor-based approaches with detailed information on sensor development. Similarly, this book also covers the mechanisms of different conventional and emerging herbal and nano therapies used in cancer treatment. The authors discuss applications of different computational and mathematical tools, such as machine-learning methods, that can be employed in cancer diagnosis and therapy at the level of personalized medicine. Features: Offers an integrated approach to provide information about all aspects of cancer biology, diagnosis, and therapy Focuses on both conventional and emerging tools/techniques applicable in cancer screening and diagnosis Covers the mechanisms of conventional and emerging anticancer drugs and therapies Provides insights about a personalized medicine-based approach in cancer diagnosis and therapy This book is essential for university students, course lecturers, researchers, and industrialists working in the fields of cancer biology, medicine, and pharmacology.
Book Synopsis Cytotoxic Payloads for AntibodyDrug Conjugates by : David E Thurston
Download or read book Cytotoxic Payloads for AntibodyDrug Conjugates written by David E Thurston and published by Royal Society of Chemistry. This book was released on 2019-07-11 with total page 502 pages. Available in PDF, EPUB and Kindle. Book excerpt: Antibody–drug conjugates (ADCs) represent one of the most promising and exciting areas of anticancer drug discovery. Five ADCs are now approved in the US and EU [i.e., ado-trastuzumab emtansine (KadcylaTM), brentuximab vedotin (AdcetrisTM), inotuzumab ozogamicin (BesponsaTM), gemtuzumab ozogamicin (MylotargTM) and moxetumomab pasudotox-tdfk (Lumoxiti®)] and over 70 others are in various stages of clinical development, with impressive interim results being reported for many. The technology is based on the concept of delivering a cytotoxic payload selectively to cancer cells by attaching it to an antibody targeted to antigens on the cell surfaces. This approach has several advantages including the ability to select patients as likely responders based on the presence of antigen on the surface of their cancer cells and a wider therapeutic index, given that ADC targeting enables a more efficient delivery of cytotoxic agents to cancer cells than can be achieved by conventional chemotherapy, thus minimising systemic toxicity. Although there are many examples of antibodies that have been developed for this purpose, along with numerous linker technologies used to attach the cytotoxic agent to the antibody, there is presently a relatively small number of payload molecules in clinical use. The purpose of this book is to describe the variety of payloads used to date, along with a discussion of their advantages and disadvantages and to provide information on novel payloads at the research stage that may be used clinically in the future.
Book Synopsis Hypoxia in Cancer: Significance and Impact on Cancer Therapy by : Sukhes Mukherjee
Download or read book Hypoxia in Cancer: Significance and Impact on Cancer Therapy written by Sukhes Mukherjee and published by Springer Nature. This book was released on 2023-04-13 with total page 452 pages. Available in PDF, EPUB and Kindle. Book excerpt: This book reviews the central role of hypoxia in cancer initiation and progression. It discusses the mechanisms of hypoxia in chemoresistance, radioresistance, angiogenesis, vasculogenesis, metastasis, metabolic, and genomic instability. It also explores the potential of hypoxia in the diagnosis and treatment of cancer. The book provides an overview of hypoxia imaging, its biological relevance, and mechanism of action. It helps in understanding the molecular mechanisms of the regulation of senescence by hypoxia. It explores the contribution of hypoxia to immune resistance and immune suppression/tolerance and determines the hypoxia-responsive long non-coding RNAs in regulating hypoxic gene expression at chromatin, transcriptional, and post-transcriptional levels. Further, it presents the functional link between hypoxia and miRNA expressions and hypoxia-regulated miRNAs in cancer cell survival in a low oxygen environment. Lastly, it discusses the applications of tumor-on-a-chip technology for the understanding of hypoxia-tumor microenvironment. This book is a valuable source for oncologists and scientists working to understand the role of hypoxia in cancer and therapeutic approaches.
Book Synopsis Innovations for Next-Generation Antibody-Drug Conjugates by : Marc Damelin
Download or read book Innovations for Next-Generation Antibody-Drug Conjugates written by Marc Damelin and published by Springer. This book was released on 2018-05-29 with total page 357 pages. Available in PDF, EPUB and Kindle. Book excerpt: Antibody-drug conjugates (ADCs) stand at the verge of a transformation. Scores of clinical programs have yielded only a few regulatory approvals, but a wave of technological innovation now empowers us to overcome past technical challenges. This volume focuses on the next generation of ADCs and the innovations that will enable them. The book inspires the future by integrating the field’s history with novel strategies and cutting-edge technologies. While the book primarily addresses ADCs for solid tumors, the last chapter explores the emerging interest in using ADCs to treat other diseases. The therapeutic rationale of ADCs is strong: to direct small molecules to the desired site of action (and away from normal tissues) by conjugation to antibodies or other targeting moieties. However, the combination of small and large molecules imposes deep complexity to lead optimization, pharmacokinetics, toxicology, analytics and manufacturing. The field has made significant advances in all of these areas by improving target selection, ADC design, manufacturing methods and clinical strategies. These innovations will inspire and educate scientists who are designing next-generation ADCs with the potential to transform the lives of patients.
Book Synopsis Regulatory Aspects of Gene Therapy and Cell Therapy Products by : Maria Cristina Galli
Download or read book Regulatory Aspects of Gene Therapy and Cell Therapy Products written by Maria Cristina Galli and published by Springer Nature. This book was released on 2023-08-01 with total page 243 pages. Available in PDF, EPUB and Kindle. Book excerpt: This book discusses the different regulatory pathways for Advanced Therapy Medicinal Products implemented by national agencies in North and South America, Europe and Asia and by international bodies in the effort of international harmonization. This book represents an update of the first edition, as it covers regulatory novelties and accumulated experience in the regions already addressed. In addition, this new edition offers a wider international perspective: new chapters are included covering Advanced Therapy Medicinal Products regulations in India, Malaysia, Spain and Thailand, the European Pharmacopoeia texts for gene therapy medicinal products as well as international harmonization programs. Each chapter, authored by experts from various regulatory bodies throughout the international community, walks the reader through the applications of nonclinical research to translational clinical research to licensure and therapeutic use of these innovative products. More specifically, each chapter offers insights into fundamental considerations that are essential for developers of Advanced Therapy Medicinal Products in the areas of product quality, pharmacology and toxicology, clinical trial design and HTA pathways, as well as pertinent ‘must-know’ guidelines and regulations. Regulatory Aspects of Gene Therapy and Cell Therapy Products: a Global Perspective is part of the American Society of Gene & Cell Therapy sub-series of the highly successful Advances in Experimental Medicine and Biology series. It is essential reading for graduate students, clinicians, and researchers interested in gene and cell therapy and the regulation of pharmaceuticals.
Book Synopsis Rare Diseases and Orphan Products by : Institute of Medicine
Download or read book Rare Diseases and Orphan Products written by Institute of Medicine and published by National Academies Press. This book was released on 2011-04-03 with total page 442 pages. Available in PDF, EPUB and Kindle. Book excerpt: Rare diseases collectively affect millions of Americans of all ages, but developing drugs and medical devices to prevent, diagnose, and treat these conditions is challenging. The Institute of Medicine (IOM) recommends implementing an integrated national strategy to promote rare diseases research and product development.
Book Synopsis Good Research Practice in Non-Clinical Pharmacology and Biomedicine by : Anton Bespalov
Download or read book Good Research Practice in Non-Clinical Pharmacology and Biomedicine written by Anton Bespalov and published by Springer Nature. This book was released on 2020-01-01 with total page 424 pages. Available in PDF, EPUB and Kindle. Book excerpt: This open access book, published under a CC BY 4.0 license in the Pubmed indexed book series Handbook of Experimental Pharmacology, provides up-to-date information on best practice to improve experimental design and quality of research in non-clinical pharmacology and biomedicine.
